MRNA · Full Picture

Moderna, Inc. — the full picture

Earnings window · 2026-07-10 to 2026-08-20 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Litigation Settlement Exposure · Litigation & settlementsPriority 93
   -18.4% net_income; 3 sources (news, press_release, sec_filing); 3 forward row(s); structured_verified
   Moderna, Inc. could be required to make an additional payment of up to $1.3 billion depending on the outcome of the appeal related to 28 U.S.C. § 1498.
2. Product / Drug Pipeline Progress · Products & launchesPriority 88
   +103.5% revenue; 3 sources (news, press_release, sec_filing); 9 forward row(s); quote_verified
   mFLUSIVA is projected to have $1 billion peak sales in the Seeking Alpha piece.
3. Liquidity and Cash Position · Liquidity & cash positionPriority 84
   -22.4% cash (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
   Year-end cash and investments for 2026 are now projected to be $4.7 to $5.2 billion, an improvement of approximately $0.2 billion.
4. Operating Expense Trends · Operating expenses (SG&A)Priority 84
   +117.2% operating_income; 3 sources (news, press_release, sec_filing); 3 forward row(s); structured_verified
   Research and development expenses for 2026 are now anticipated to be approximately $2.9 billion, lowered from approximately $3.0 billion.
5. Revenue Performance and Mix · Revenue growth & mixPriority 82
   -13.8% revenue (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
   Seeking Alpha reports expectations of a $2 per share loss and a 28% decline in revenue to $103M for Q2.
6. Gross Margin Drivers · Gross marginPriority 77
   +58.6% operating_income; 2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge.
7. Outstanding Indebtedness · Debt, leverage & refinancingPriority 76
   -18.6% liability; 2 forward row(s); quote_verified
   In November 2025, Moderna entered into a Credit and Guaranty Agreement providing for aggregate term loan commitments of $1.5 billion.
8. Guidance / Outlook · Guidance & outlookPriority 74
   3 sources (news, press_release, sec_filing); 9 forward row(s); quote_verified
   The Company is targeting up to 10% revenue growth from 2025 revenue in 2026.
9. Manufacturing And Capacity · Supply chain & operationsPriority 73
   -8.0% liability; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
   Future minimum lease payments under non-cancelable lease agreements total minimum payments of $1,030 million as of June 30, 2026.
10. Regulatory Approval Milestones · Regulatory action & investigationsPriority 73
    3 sources (news, press_release, sec_filing); 8 forward row(s); quote_verified
    The Company anticipates potential approval of mFLUSIVA with the August 5th PDUFA date.
11. Supply Chain And Inventory · Supply chain & operationsPriority 67
    -54.5% net_income (realized); structured_verified
    Moderna, Inc. recorded inventory write-downs of $79 million in the six months ended June 30, 2026 primarily related to finished and semi-finished vaccine inventory and raw materials due to updated demand forecasts, shelf-life expiration and other adjustments.
12. Capital Expenditures Program · Capital expenditurePriority 64
    2 sources (press_release, sec_filing); 2 forward row(s); quote_verified
    Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion.

Threads by pillar

Revenue & Demand Priority 95 · 6 threads

• Product / Drug Pipeline ProgressPriority 88 · News, Release, Filing
• Revenue Performance and MixPriority 82 · News, Release, Filing
• Market Demand TrendsPriority 62 · News, Filing
• Customer DynamicsPriority 47 · News
• Distribution ChannelsPriority 14 · Filing
• Geographic Market CommentaryPriority 45 · Release

Costs & Margins Priority 92 · 4 threads

• Operating Expense TrendsPriority 84 · News, Release, Filing
• Manufacturing And CapacityPriority 73 · Release, Filing
• Supply Chain And InventoryPriority 67 · Filing
• Gross Margin DriversPriority 77 · Release, Filing

Capital & Balance Sheet Priority 92 · 4 threads

• Liquidity and Cash PositionPriority 84 · News, Release, Filing
• Outstanding IndebtednessPriority 76 · Filing
• Capital Expenditures ProgramPriority 64 · Release, Filing
• Income Tax Rate ChangesPriority 41 · Filing

Strategy & Portfolio Priority 45 · 1 thread

• Licensing / Collaboration DealsPriority 45 · News, Release, Filing

Legal, Regulatory & Policy Priority 96 · 4 threads

• Litigation Settlement ExposurePriority 93 · News, Release, Filing
• Litigation and Legal RiskPriority 56 · News
• Regulatory Approval MilestonesPriority 73 · News, Release, Filing
• Patent Infringement LawsuitPriority 29 · News

Guidance & Outlook Priority 74 · 1 thread

• Guidance / OutlookPriority 74 · News, Release, Filing

Expected impact by metric